Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of a $57.5M Series D financing round with leading global investors.